DDW’s Diana Spencer examines the role of mass spectrometry in drug discovery and development.

By measuring the mass-to-charge ratio of ions, mass spectrometry (MS) can identify unknown compounds, quantify known ones, and reveal the structure and chemical properties of molecules. It is highly sensitive and precise, making it an invaluable tool for identifying the composition of organic molecules. In drug discovery, MS aids in detecting and characterising drug compounds, their metabolites, and potential binding partners, allowing scientists to transform promising molecules into effective therapeutics.

AI integration

One company active in the MS market, Agilent, has recently introduced AI Peak Integration for MassHunter data analysis for GC/SQ with the aim of streamlining data processing and review times.

Shweta Shukradas, Director, Mass Spectrometry Marketing, and Mike Knierman, Biopharma Workflow Manager, Mass Spec division, Agilent, comments: “In the rapidly evolving landscape of drug discovery and development, laboratories face the dual challenge of reducing costs while accelerating research. Automation and intelligent technologies play a pivotal role in meeting these demands.”

The company’s Flash Characterization technique generates reaction products directly in the electrospray, and is designed to reduce long incubation periods and streamline workflows. The addition of electron-capture dissociation (ECD) fragmentation facilitates the breakdown of larger proteins and preserves fragile post-translational modifications (PTMs) during fragmentation. The company has also integrated RapidFire and dual needle LC autosamplers into its mass spectrometry platforms, adding rapid analysis capabilities.

Trapped ion mobility spectrometry

Bruker’s MS offering ranges from liquid chromatography tandem MS (LC-MS/MS) and ion trap MS to matrix-assisted laser desorption/ionisation (MALDI) time-of-flight (TOF) MS. 

Its Trapped Ion Mobility Spectrometry (TIMS) technology enables rapid gas-phase separation of isobars and isomers, by exploiting the molecular collisional cross-section. timsTOF MPP uses a dual MALDI / ESI ion source with a 10kHz smartbeam 3D laser to enable uHTS compatible speed and throughput. The rapifleX MPP is designed for automatic handling of 384 and 1536 sample plates to screen more than a million compounds in a week.

Self-assembled monolayers in high-density biochip arrays

Zachary Gurard-Levin, PhD, Science Director, Discovery, Charles River says that: “Historically, MS instruments have not always been amenable to the components required for optimal activity in a biochemical or binding reaction. Purification of analytes prior to detection can be cumbersome and time-consuming.”

The company uses self-assembled monolayers in high-density biochip arrays combined with MALDI MS, to promote the immobilisation of the analyte(s) of interest out of a complex reaction. The SAMDI technology is amenable to any buffer component, encouraging the optimisation of the assay based on the biological needs of the target. 

“Affinity selection MS (ASMS) to identify small molecule binders to protein, oligonucleotide, and cellular targets, is promising,” Gurard-Levin adds. “Traditional ASMS workflows rely on multiple sample preparation steps, so researchers often pool hundreds of compounds in a single reaction, which may promote compound misbehaviour and higher false positive rates.” 

High resolution ion mobility MS

MOBILion’s high-resolution ion mobility mass spectrometry (HRIM-MS) platform utilises SLIM (structures for lossless ion manipulation), which was pioneered by physical chemist Dr Richard Smith, Director of Proteomics Research at the Pacific Northwest National Laboratory. SLIM makes ions turn corners,   and this enables a single-pass flight path up to 13 metres, providing resolving powers of >250 that can distinguish differences as small as 0.2% in collision cross section (CCS) values.

Acoustic ejection MS

“Mass spectrometry plays a pivotal role in ensuring both accuracy and quality of compounds during the drug discovery process,” says Lori Stansberry, Director, Global Market Development, Pharma & Biopharma at SCIEX. “It’s important to help our customers identify potential issues early and optimise their drug candidates.”

The SCIEX Echo MS+ system combines proprietary Acoustic Ejection Mass Spectrometry technology with the SCIEX ZenoTOF 7600 system or SCIEX Triple Quad 6500+ system to deliver qualitative and quantitative results, through an expanded panel of robust high-throughput assays. The SCIEX ZenoTOF 7600 system combines several features aimed at enhancing analytical precision and speed.

To demonstrate the capability of the system, a high-speed compound quality assessment experiment was set up using the Echo MS+ system with ZenoTOF 7600 system, and 45 compounds were rapidly identified using both polarities in less than four minutes. Compounds were confidently assessed using a combination of mass accuracy and isotope ratio pattern.

Affinity selection MS

“Mass spectrometry is the cornerstone of modern drug discovery, providing invaluable insights into the molecular composition and behaviour of potential therapeutics. With its unparalleled ability to identify hits by affinity and mass with utmost precision (such as ASMS), mass spectrometry will continue to accelerate the identification, characterisation, and optimisation of novel drug candidates, paving the way for transformative breakthroughs in medicine,” says Dr John Unitt, VP Inflammation & Immunology at Sygnature Discovery.

MS-based biophysical assays have emerged as powerful hit-finding techniques. Affinity Selection Mass Spectrometry (ASMS) from Sygnature Discovery is designed to screen pooled compounds to identify ligands. ASMS is a label-free, in-solution method broadly applicable to diverse target classes, including non-protein targets, such as nucleic acids. It allows screening of large numbers of lead-like molecules and, unlike DNA-encoded library (DEL) screening, allows direct follow-up from DMSO or solid stock without waiting for the resynthesis off-DNA.

Orbitrap-based LC-MS

Another company active in the MS market is Thermo Fisher Scientific, which produces MS instruments, software and supplies for use in drug discovery. This includes a range of liquid chromatography (LC)-MS instruments for proteomics and metabolomics, clinical research and pharmaceutical process monitoring. Triple quadrupoles are widely used in life science research and routine analyses such as food testing, environmental analysis and pharmaceutical quality control, these include TSQ Quantiva, TSQ Quantum and TSQ Endura. The company’s linear ion traps, the Velos Pro Linear Ion Trap and LTQ XL Linear Ion Trap, are used for screening for unknown compounds, peptide identification, measuring drug metabolism, determining structure of small molecules.

The company also makes Orbitrap-based LC-MS instruments. This has been designed to perform challenging quantitative and qualitative analyses at high resolution. 

Multi-reflecting time-of-flight MS

In the MS field, Waters Corporation offer the ACQUITY QDa II Mass Detector and the Waters Xevo TQ Absolute MS and has recently introduced advanced multi-reflecting time-of-flight (MRT) MS in a benchtop format.

Mr James Hallam, Vice President for Research, Development, and Advanced Testing, Waters Corporation, reveals: “MS innovation at Waters is fuelled by the need to accelerate drug discovery and development programs, ensuring safe, efficacious, and economical patient outcomes. We prioritised the accessibility and seamless integration of mass detection, the suitability of MS across the complex landscape of new and emerging modalities, and the removal of compromises for advanced MS research.”

From DDW Volume 25 – Issue 3, Summer 2024 Read the digital issue